Home Trending Signal Garden News Market Predictions Sources About

Loading...

Hanami·AI-powered crypto news & signals

© 2026 Hanami · All rights reserved

9926

AI-powered news analysis from 85+ sources

articles

1

Long

1

Short

0

n

news9/2news

Ivonescimab Meets Overall Survival Key Secondary Endpoint in Interim Analysis of Phase III HARMONi-2 Study, Demonstrating Statistically Significant and Clinically Meaningful Benefit Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC

95·A+Long